{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:10:34Z","timestamp":1793661034948,"version":"4.5.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,8,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class inhibitor of ataxia telangiectasia and Rad3-related protein kinase (ATR). We assessed multiple ascending doses of berzosertib\u2009+\u2009gemcitabine \u00b1\u2009cisplatin in patients with resistant\/refractory advanced solid tumours.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We evaluated the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of intravenous berzosertib\u2009+\u2009gemcitabine\u2009\u00b1\u2009cisplatin using a standard 3\u2009+\u20093 dose-escalation design. The starting doses were berzosertib 18\u2009mg\/m<jats:sup>2<\/jats:sup>, gemcitabine 875\u2009mg\/m<jats:sup>2<\/jats:sup> and cisplatin 60\u2009mg\/m<jats:sup>2<\/jats:sup>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty-two patients received berzosertib\u2009+\u2009gemcitabine and eight received berzosertib\u2009+\u2009gemcitabine\u2009+\u2009cisplatin. Four patients receiving berzosertib\u2009+\u2009gemcitabine had a total of seven dose-limiting toxicities (DLTs) and three receiving berzosertib\u2009+\u2009gemcitabine\u2009+\u2009cisplatin had a total of three DLTs. Berzosertib 210\u2009mg\/m<jats:sup>2<\/jats:sup> (days 2 and 9)\u2009+\u2009gemcitabine 1000\u2009mg\/m<jats:sup>2<\/jats:sup> (days 1 and 8) Q3W was established as the recommended Phase 2 dose (RP2D); no RP2D was determined for berzosertib\u2009+\u2009gemcitabine\u2009+\u2009cisplatin. Neither gemcitabine nor cisplatin affected berzosertib PK. Most patients in both arms achieved a best response of either partial response or stable disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Berzosertib\u2009+\u2009gemcitabine was well tolerated in patients with advanced solid tumours and showed preliminary efficacy signs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical trial identifier<\/jats:title>\n                <jats:p>NCT02157792.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-021-01405-x","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T17:53:27Z","timestamp":1622656407000},"page":"510-519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours"],"prefix":"10.1038","volume":"125","author":[{"given":"Mark R.","family":"Middleton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R. J.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-4095","authenticated-orcid":false,"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart S.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Diaz-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0107-1444","authenticated-orcid":false,"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"1405_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","volume":"33","author":"CA Rabik","year":"2007","unstructured":"Rabik, C. A. & Dolan, M. E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33, 9\u201323 (2007).","journal-title":"Cancer Treat. Rev."},{"key":"1405_CR2","first-page":"CD011044","volume":"3","author":"V Chin","year":"2018","unstructured":"Chin, V., Nagrial, A., Sjoquist, K., O\u2019Connor, C. A., Chantrill, L., Biankin, A. V. et al. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst. Rev. 3, CD011044 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1405_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","volume":"81","author":"AJ Cortez","year":"2018","unstructured":"Cortez, A. J., Tudrej, P., Kujawa, K. A. & Lisowska, K. M. Advances in ovarian cancer therapy. Cancer Chemother. Pharm. 81, 17\u201338 (2018).","journal-title":"Cancer Chemother. Pharm."},{"key":"1405_CR4","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1093\/annonc\/mdw271","volume":"27","author":"MD Hellmann","year":"2016","unstructured":"Hellmann, M. D., Li, B. T., Chaft, J. E. & Kris, M. G. Chemotherapy remains an essential element of personalized care for persons with lung cancers. Ann. Oncol. 27, 1829\u20131835 (2016).","journal-title":"Ann. Oncol."},{"key":"1405_CR5","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2217\/pgs-2017-0117","volume":"18","author":"JR Jhan","year":"2017","unstructured":"Jhan, J. R. & Andrechek, E. R. Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics 18, 1595\u20131609 (2017).","journal-title":"Pharmacogenomics"},{"key":"1405_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4046\/trd.2018.0068","volume":"82","author":"SH Lee","year":"2019","unstructured":"Lee, S. H. Chemotherapy for Lung Cancer in the Era of Personalized Medicine. Tuberc. Respir. Dis. 82, 179\u2013189 (2019).","journal-title":"Tuberc. Respir. Dis."},{"key":"1405_CR7","doi-asserted-by":"publisher","first-page":"175883591878665","DOI":"10.1177\/1758835918786658","volume":"10","author":"A Minchom","year":"2018","unstructured":"Minchom, A., Aversa, C. & Lopez, J. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther. Adv. Med Oncol. 10, 1758835918786658 (2018).","journal-title":"Ther. Adv. Med Oncol."},{"key":"1405_CR8","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers6031769","volume":"6","author":"G Housman","year":"2014","unstructured":"Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N. et al. Drug resistance in cancer: an overview. Cancers 6, 1769\u20131792 (2014).","journal-title":"Cancers"},{"key":"1405_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000086183","volume":"14","author":"YA Luqmani","year":"2005","unstructured":"Luqmani, Y. A. Mechanisms of drug resistance in cancer chemotherapy. Med Princ. Pr. 14, 35\u201348 (2005).","journal-title":"Med Princ. Pr."},{"key":"1405_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","volume":"127","author":"M Kwok","year":"2016","unstructured":"Kwok, M., Davies, N., Agathanggelou, A., Smith, E., Oldreive, C., Petermann, E. et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood 127, 582\u2013595 (2016).","journal-title":"Blood"},{"key":"1405_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.573","volume":"7","author":"PM Reaper","year":"2011","unstructured":"Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J. D., Maccormick, S., Charlton, P. A. et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 7, 428\u2013430 (2011).","journal-title":"Nat. Chem. Biol."},{"key":"1405_CR12","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nsmb.2076","volume":"18","author":"LI Toledo","year":"2011","unstructured":"Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S. et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 18, 721\u2013727 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1405_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","volume":"149","author":"AM Weber","year":"2015","unstructured":"Weber, A. M. & Ryan, A. J. ATM and ATR as therapeutic targets in cancer. Pharm. Thera 149, 124\u2013138 (2015).","journal-title":"Pharm. Thera"},{"key":"1405_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.181","volume":"3","author":"E Fokas","year":"2012","unstructured":"Fokas, E., Prevo, R., Pollard, J. R., Reaper, P. M., Charlton, P. A., Cornelissen, B. et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 3, e441 (2012).","journal-title":"Cell Death Dis."},{"key":"1405_CR15","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.18632\/oncotarget.2158","volume":"5","author":"AB Hall","year":"2014","unstructured":"Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B., Gu, Y. et al. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget 5, 5674\u20135685 (2014).","journal-title":"Oncotarget"},{"key":"1405_CR16","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1158\/1535-7163.MCT-18-0470","volume":"17","author":"X Tu","year":"2018","unstructured":"Tu, X., Kahila, M. M., Zhou, Q., Yu, J., Kalari, K. R., Wang, L. et al. ATR inhibition is a promising radiosensitizing strategy for triple-negative breast cancer. Mol. Cancer Ther. 17, 2462\u20132472 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"1405_CR17","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","volume":"38","author":"TA Yap","year":"2020","unstructured":"Yap, T. A., O\u2019Carrigan, B., Penney, M. S., Lim, J. S., Brown, J. S., de Miguel Luken, M. J. et al. Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors. J. Clin. Oncol. 38, 3195\u20133204 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1405_CR18","doi-asserted-by":"crossref","unstructured":"Scagliotti, G. V., Parikh, P. Pawel, Jv., Biesma, B., Vansteenkiste, J., Manegold, C. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non\u2013small-cell lung cancer. J. Clin. Oncol. 26, 3543\u20133551 (2008)..","DOI":"10.1200\/JCO.2007.15.0375"},{"key":"1405_CR19","unstructured":"EMC. Gemcitabine 10 mg\/ml, solution for infusion. Summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/7298\/smpc#POSOLOGY (2019)."},{"key":"1405_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1405_CR21","doi-asserted-by":"crossref","unstructured":"Plummer, E. R., Dean, E. J., Evans, T. R. J., Greystoke, A., Herbschleb, K., Ranson, M. et al. Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792). J. Clin. Oncol. 34, Abstract 2513 (2016).","DOI":"10.1200\/JCO.2016.34.15_suppl.2513"},{"key":"1405_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","volume":"135","author":"F Griesinger","year":"2019","unstructured":"Griesinger, F., Korol, E. E., Kayaniyil, S., Varol, N., Ebner, T. & Goring, S. M. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 135, 196\u2013204 (2019).","journal-title":"Lung Cancer"},{"key":"1405_CR23","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","volume":"36","author":"A Thomas","year":"2018","unstructured":"Thomas, A., Redon, C. E., Sciuto, L., Padiernos, E., Ji, J., Lee, M. J. et al. Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors. J. Clin. Oncol. 36, 1594\u20131602 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1405_CR24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1101\/gad.290957.116","volume":"31","author":"SA Yazinski","year":"2017","unstructured":"Yazinski, S. A., Comaills, V., Buisson, R., Genois, M. M., Nguyen, H. D., Ho, C. K. et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 31, 318\u2013332 (2017).","journal-title":"Genes Dev."},{"key":"1405_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"The Cancer Genome Atlas Research Network.","year":"2014","unstructured":"The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543\u2013550 (2014).","journal-title":"Nature"},{"key":"1405_CR26","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ctrv.2012.12.001","volume":"39","author":"N Turner","year":"2013","unstructured":"Turner, N., Moretti, E., Siclari, O., Migliaccio, I., Santarpia, L., D\u2019Incalci, M. et al. Targeting triple negative breast cancer: is p53 the answer? Cancer Treat. Rev. 39, 541\u2013550 (2013).","journal-title":"Cancer Treat. Rev."},{"key":"1405_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretic, L., Kong, G. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47\u201353 (2015).","journal-title":"Nature"},{"key":"1405_CR28","doi-asserted-by":"crossref","unstructured":"Konstantinopoulos, P. A., Cheng, S. C., Wahner Hendrickson, A. E., Penson, R. T., Schumer, S. T., Doyle, L. A. et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, Phase 2 trial.\u00a0Lancet Oncol.\u00a021, 957\u2013968 (2020).","DOI":"10.1016\/S1470-2045(20)30180-7"},{"key":"1405_CR29","doi-asserted-by":"crossref","unstructured":"Thomas, A., Takahashi, N., Rajapakse, V. N., Zhang, X., Sun, Y., Ceribelli, M.et al. Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer Cell 39, 566\u2013579.e7 (2021).","DOI":"10.1016\/j.ccell.2021.02.014"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01405-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01405-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01405-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T23:27:50Z","timestamp":1629156470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01405-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8,17]]}},"alternative-id":["1405"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01405-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"5 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the ethical principles of the International Council for Harmonization guideline for Good Clinical Practice, the Declaration of Helsinki and applicable local regulations. All patients provided written informed consent before any study procedures were performed. The study sites received ethical approval from the following institutional review boards\/independent ethical committees: NRES Committee North East\u2014Sunderland, and Institutional Review Board\/Dana-Farber Cancer Institute.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Any requests for data by qualified scientific and medical researchers for legitimate research purposes will be subject to the Merck KGaA, Darmstadt, Germany Data Sharing Policy. All requests should be submitted in writing to the Merck KGaA, Darmstadt, Germany data-sharing portal (). When Merck KGaA, Darmstadt, Germany has a co-research, co-development or co-marketing or co-promotion agreement, or when the product has been outlicensed, the responsibility for disclosure might be dependent on the agreement between parties. Under these circumstances, Merck KGaA, Darmstadt, Germany, will endeavour to gain agreement to share data in response to requests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"M.R.M. reports personal fees from Amgen, grants and personal fees from Roche, grants from AstraZeneca, grants and personal fees from GSK, personal fees and other from Novartis, other from Millenium, personal fees, non-financial support and other from Immunocore, personal fees and other from BMS, personal fees and other from Eisai, other from Pfizer, personal fees, non-financial support and other from Merck\/MSD, personal fees and other from Rigontec (acquired by MSD), other from Regeneron, personal fees from BiolineRx, personal fees and other from Array Biopharma (now Pfizer), non-financial support and other from Replimune, personal fees from Kineta and personal fees from Silicon Therapeutics, outside the submitted work. E.D. was an employee of The University of Manchester and The Christie NHS Foundation Trust, Manchester, at the time of study; Current address: Oncology R&D, AstraZeneca, Cambridge and Alderley Park, UK. T.R.J.E. has received honoraria for speaking engagements and attending advisory boards paid to his institution, and support from Merck Sharp & Dohme to attend international medical conferences. G.I.S. has received research funding from Eli Lilly, Merck KGaA\/EMD Serono, Merck & Co., Inc. and Sierra Oncology, and honoraria for serving on advisory boards on behalf of Pfizer, Eli Lilly, G1 Therapeutics, Roche, Merck KGaA\/EMD Serono, Sierra Oncology, Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Astex, Almac, Ipsen, Bayer, Angiex, Daiichi Sankyo, Boehringer Ingelheim, ImmunoMet, Artios and Asana. J.P. was an employee of Vertex Pharmaceuticals Europe Ltd, Abingdon, UK, at the time of manuscript preparation. He holds stock in Vertex Pharmaceuticals Inc. Current address: Bayer plc, Reading, UK. B.H. was an employee of EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany at the time of manuscript preparation; Current address: Novartis Institutes for BioMedical Research, Cambridge, MA, USA. M.F. was an employee of Merck KGaA, Darmstadt, Germany, at the time of manuscript preparation. Current address: CureVac, T\u00fcbingen, Germany. I.D.-P. was an employee of Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany, at the time of manuscript preparation. Current address: GlaxoSmithKline, Zug, Switzerland. R.P. reports honoraria for serving on advisory boards on behalf of Vertex and Merck KGaA relating to this compound, reimbursement for her institution for clinical trial costs, consultancy services to Pierre Faber, Bayer, Octimet, Clovis Oncology, Novartis, Karus Therapeutics, Biosceptre, BMS, Cybrexa, Ellipses, CV6 Therapeutics, Astex Therapeutics and Sanofi Aventis and research funding from AstraZeneca.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Financial support for this study was initially provided by Vertex Pharmaceuticals Inc., Boston, MA, USA, and subsequently by Merck KGaA, Darmstadt, Germany. Medical writing assistance was provided by Alexander T. Hardy from Bioscript Stirling Ltd, Macclesfield, UK and funded by Merck KGaA, Darmstadt, Germany.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}